

From: [Wood, Lorraine](#)
To: [Ammons, Stanley](#)
Subject: Information Request for BLA 125612: PK Parameters
Date: Wednesday, October 26, 2016 2:32:00 PM
Attachments: [image001.png](#)
[image002.jpg](#)
[image003.jpg](#)
[image004.jpg](#)
[image005.jpg](#)
[image006.jpg](#)
Importance: High

Dear Mr. Ammons,

We are reviewing your submission for BLA 125612 and we request the following information to continue our review:

A prospective, controlled, randomized, crossover study investigating the pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan P/RiaSTAPTTM in patients with congenital fibrinogen deficiency (**FORMA-01**).

1. Please recalculate the PK parameters of Octafibrin and Haemocomplettan[®] P/RiaSTAPTTM above LOQ ((b) (4)). In a Tabulated form, please provide age, weight, individual concentration-time data, and estimated PK parameters.
2. Please provide individual and mean concentration-time plots of Octafibrin and Haemocomplettan (above LOQ).
3. Please explore the relationship between plasma concentration (IVR at one hour) and maximum clot strength (which is also at one hour). For this analysis please use the data from studies FORMA-01 and FORMA-02. In a tabulated form, please submit the data (IVR and MCT) for individual subject.
4. When will you be able to submit the complete study report FORMA-04 (this study is ongoing) and what happened to FORMA-03?

Thank you

Lorraine D. Wood, MS, MLS(ASCP)^{CM}
Regulatory Project Manager

Center for Biologics Evaluation and Research
Office of Blood Research and Review
U.S. Food and Drug Administration
Tel: 240-402-8439
lorraine.wood@fda.hhs.gov

cid:image001.png@01D1C57E.DFA022A0



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.